CV Outcomes with PCSK9 Inhibitors: selecting the right patient
Details & Video
Program Time: 30 minutes
Accreditation-CME Credits: This online 1-credit-per-hour Self-Learning program has been certified by the College of Family
Physicians of Canada for up to 0.5 Mainpro+ credits.
Target Audience: General Practitioners
Program available until: July 11, 2019
Overview & Objectives
CV Outcomes With PCSK9 Inhibitors
Target Audience: General Practitioners.
By participating in this educational program, health care providers will be able to:
- EXPLAIN the results of the PCSK9 inhibitor outcomes trials
- DEFINE the appropriate patient for PCSK9 inhibitors
Accreditation
This online 1-credit-per-hour Self-Learning program has been certified by the College of Family
Physicians of Canada for up to 0.5 Mainpro+ credits.
This program was supported in part by educational funding from Amgen Canada
Claiming your credits: Please submit your credits for this activity online at www.cfpc.ca/login. Please retain proof of your participant for six (6) years in case you are selected to participate in credit validation or auditing.
This program was supported in part by educational funding from Amgen Canada
Claiming your credits: Please submit your credits for this activity online at www.cfpc.ca/login. Please retain proof of your participant for six (6) years in case you are selected to participate in credit validation or auditing.
Planning Committee & Faculty
Planning Committee & Faculty
Milan Gupta
MD, FRCPC, FCCS
Associate Clinical Professor of Medicine,
McMaster University
Medical Director
Canadian Collaborative Research Network
View disclosures
Jeffrey Habert
MD, CCFP, FCFP
Assistant Professor,
University of Toronto,
Dept. of Family and Community Medicine
View disclosures
Daniel Ngui
BSc (P.T), MD, CFPC, FCFP
Clinical Associate Professor
University of British Columbia
Medical Director
Fraser Street Medical
View disclosures
Marla Shapiro
C.M., MDCM, CCFP, MHSc, FRCPC, FCFP, NCMP
Professor, University of Toronto
Department of Family and Community Medicine
University Health Network
North York General, Mount Sinai
View disclosures
Agenda
Agenda
| Program Chapter | Duration (Min:Sec) |
|---|---|
| Introduction | 2:10 |
| Landscape of PCSK9 Inhibitors | 3:40 |
| PCSK9 Inhibitor Trials: Fourier | 3:54 |
| PCSK9 Inhibitor Trials: SPIRE 1 and 2 | 2:41 |
| PCSK9 Inhibitor Trials: ODYSSEY | 4:59 |
| PCSK9 Inhibitor Guidelines | 4:28 |
| Which Patients Deserve a PCSK9 Inhibitor? | 0:46 |
Sponsorship
This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and is supported through an educational grant received from:
Amgen Canada
Links & Resources
Links & Resources:
- Kotseva, K. et al European Journal of Preventive Cardiology, February 16, 2015.
- deGoma, et al. “Circulation. Cardiovascular Genetics 9, no. 3 (June 2016): 240–49.
- Pijlman, A. H., et al. Atherosclerosis 209, no. 1 (March 2010): 189–94.
- Anderson, T, et al. Canadian Journal of Cardiology 32, no. 11 (November 2016): 1263–82.
- Sabatine, M., et al. New England Journal of Medicine 372, no. 16 (April 16, 2015): 1500–1509.
- Nicholls, S., et al. JAMA 316, no. 22 (December 13, 2016): 2373–84.
- Sabatine MS, et al. N Engl J Med. 2017 May 4;376(18):1713-1722.
- Ridker PM, et al. N Engl J Med. 2017 Apr 20;376(16):1527-1539.
- Steg G, et al. Am College Cardiol. 2018 Mar 10; (suppl.)
- Sabatine MS et al. N Engl J Med. 2017; epub ahead of print
- Steg G et al. American College of Cardiology Scientific Sessions, 2018 – Orlando, FL
- Schwartz GG, et al. Am Heart J 2014;168:682-689.e1.
- Anderson TJ, et al. CJC, 2016: Jul.24(32):1263-1282.
- Lloyd-Jones DM, et al. JACC, 2017: Oct.70(14).
- CCS Dyslipidemia Guidelines:
- (https://www.onlinecjc.ca/article/S0828-282X(16)30732-2/abstract)
- (http://ccs.ca/images/Guidelines/PocketGuides_EN/Pocket_Guides/Lipids%20Pocket%20Guide_2016.pdf)
- European Atherosclerosis Society: www.escardio.org/guidelines